Loading...

More Than Skin-deep: Challenges in Treating Skin and Soft Tissue Infections

More Than Skin-deep: Challenges in Treating Skin and Soft Tissue Infections

Skin and soft tissue infections (SSTIs) are ubiquitous and the most common of infections, suffered by everyone at some point to a lesser or greater degree and encountered by all doctors.” – Dryden, J. Antimicrob. Chemother. 2010: 65 (suppl 3): iii35-iii44

Skin is the human body’s largest organ. It’s a “fun fact” that many children learn. What many children don’t learn about, however, are skin and soft tissue infections, which can affect both adults and children. Skin and soft tissue infections can become serious if not treated promptly, but some of the medications used to treat such infections, such as clindamycin, can lead to noncompliance, especially in children.

Skin and soft tissue infections are common, in part because the term covers a wide range of infections. According to a 2014 article in Medscape, skin and soft tissue infections can be divided into three groups, uncomplicated, complicated but nonnecrotizing and necrotizing. Uncomplicated infections include superficial infections and minor abscesses. Complicated and necrotizing infections often require surgery and can lead to the loss of a limb or death. All three are more likely to occur in patients who are immunocompromised, such as those with HIV/AIDS, diabetes or cancer.

Clindamycin is approved and commonly prescribed to treat skin and soft tissue infections. However, this drug is not appropriate for everyone. In a 2002 study of 24 drugs, participants ranked clindamycin number 22 in terms of palatability and remembered it for its bad taste or aftertaste up to six months later. Such a bitter tasting drug could lead to medication noncompliance, especially for pediatric patients, who are more sensitive to bitter tastes.

If not quickly and properly treated, skin and soft tissue infections can become serious. Some of the medications used to treat skin and soft tissue infections, such as clindamycin, can lead to noncompliance, especially in pediatric patients.

Orbis Bisociences® can use Precision Particle FabricationTM to develop format-flexible, taste-masked medications. We can develop medications that can mask extremely bitter tastes and lead to reduced medication noncompliance. With medications like those we can develop, children with skin and soft tissue infections won’t have to experience added complications due to noncompliance caused by bitter tastes. It is our goal that children learn about such medical dangers only from books.

By | 2018-11-10T23:41:41+00:00 December 2nd, 2016|Blog|0 Comments

About the Author: